peak glp-1 Employer FAQs on the Rise of Drugs for Weight Loss and the Workplace Impact | Fisher Phillips SMA

While there has been no change in law, CMS clarified that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use

Then, attorneys on both side will gather scientific evidence and work with experts to support and counter the claims in the case

GLP-1 medications bind to GLP-1 receptors in special cells in the pancreas called pancreatic beta cells

It often improves or helps prevent obesity-related diseases, including type 2 diabetes, sleep apnea, high blood pressure, and fatty liver disease

This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request

The GI effects of GLP-1 drugs are actually part of their mechanism of action, not just unpleasant side effects